Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Genscript Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was $2,947.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-575.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech EV-to-EBIT Related Terms
Genscript Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genscript Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's EV-to-EBIT falls into.
Genscript Biotech's current Enterprise Value is $7,156.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-575.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a EV-to-EBIT of -12.44 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #999999 out of 370 companies in the Biotechnology industry.
Is Genscript Biotech's EV-to-EBIT too high?
Genscript Biotech's current EV-to-EBIT is -12.44. Based on the distribution chart, Genscript Biotech ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #999999 out of 370 companies for EV-to-EBIT. This places Genscript Biotech in the lower half of its industry. The industry median EV-to-EBIT is 16.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current EV-to-EBIT is -12.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.09, compared to a current price of $3.50 — trading 67.5% above its estimated fair value. The current EV-to-EBIT is -12.44. Genscript Biotech's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current EV-to-EBIT is -12.44 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued.
The current stock price of $3.50 is trading 67.5% above its estimated GF Value™ of $2.09.
GuruFocus considers Genscript Biotech to be Significantly Overvalued.
Key valuation signals for GNNSF:
EV-to-EBIT: -12.44
GF Value™: $2.09 vs. price of $3.50 (67.5% above fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
